• PubMed
  • April 18, 2025
  • 0 views
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial

Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…

  • PubMed
  • April 18, 2025
  • 1 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 0 views
Negative pressure wound therapy versus usual care in patients with surgical wound healing by secondary intention in the UK (SWHSI-2): an open-label, multicentre, parallel-group, randomised controlled trial

Lancet. 2025 May 10;405(10490):1689-1699. doi: 10.1016/S0140-6736(25)00143-6. Epub 2025 Apr 15. ABSTRACT BACKGROUND: Surgical wound healing by secondary intention (SWHSI) presents a substantial management and financial challenge. Negative pressure wound therapy…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…

  • PubMed
  • April 17, 2025
  • 2 views
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial

Lancet Psychiatry. 2025 May;12(5):366-376. doi: 10.1016/S2215-0366(25)00063-X. ABSTRACT BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we…